TNFRSF1A and neoplasm: In summary, we have demonstrated that utilizing an agonistic anti-4-1BB antibody to augment the TNF-R family member 4-1BB pathway during melanoma TIL expansion significantly improves the phenotype and function of tumor-reactive CD8+ CTL.